

AACR Virtual Meeting

Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application


August 17-19, 2020

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock Shareholder; SB, Speakers' Bureau; H, Honoraria; O, Other.

Last Name	First Name	Company	Relationships	Type	Role
Amati	Bruno	European Institute of Oncology, Milan, Italy	No Relationships		Speaker
Ansell	Stephen	Mayo Clinic College of Medicine	BMS, Seattle Genetics, Regeneron, AI Therapeutics, Trillium	G	Speaker
Aresu	Luca	University of Turin, Turin, Italy	No Relationships		Speaker
Arthur	Ronald	American Association for Cancer Research	No Relationships		Staff
Attar	Ricardo	Janssen Research and Development	Janssen Research & Development, LLC	E	Program Committee
Baran	Amy	American Association for Cancer Research	No Relationships		Staff
Béguelin	Wendy	Weill Cornell Medical College	No Relationships		Speaker
Bertoni	Francesco	Institute of Oncology Research, Bellizona	ADC Therapeutics, Bayer AG, Helsinn, Cellestia, NEOMED Therapeutics 1, Acerta, CTI Life Sciences, EMD Serono, ImmunoGen, Menarini Ricerche, PIQUR Therapeutics AG, HTG, Amgen, Astra Zeneca, Janssen-Cilag AG, Jazz Pharmaceuticals	C,G,O	Program Committee, Speaker
Brentjens	Renier	Memorial Sloan Kettering Cancer Center	JUNO Therapeutics, Gracell Therapeutics	C,G	Speaker




AACR Virtual Meeting

Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

August 17-19, 2020

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	Company	Relationships	Type	Role
Brown	Jennifer	Dana-Farber Cancer Institute	AbbVie, Acerta, AZ, Beigene, Catapult Therapeutics, Dynamo Therapeutics, Juno/Celgene, MEI Pharma, Octapharma, Novartis, Pfizer, Verastem, Gilead, Loxo, Sun, Invecys	C,G,O	Program Committee, Speaker
Calado	Dinis	London Research Institute, London, United Kingdom	Myricx Pharma	S	Speaker
Casola	Stefano	The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy	Verastem	G	Speaker
Cerchietti	Leandro	Weill Cornell Medical College	No Relationships		Speaker
Chapuy	Bjoern	University of Göttingen	No Relationships		Speaker
Cozen	Wendy	USC Norris Comprehensive Cancer Center	No Relationships		Speaker
Cragg	Mark	University of Southampton	Bioinvent, Roche, Gilead, UCB, Iteos, GSK, Baxalta, Merck GdA, BI, Chugai	A,C,G,H	Speaker
Dalla-Favera	Riccardo	Columbia University	Akamara Therapeutics, NeoGenomics	C	Program Committee
Davies	Andrew	University of Southampton School of Medicine	Celgene, Roche, Gilead/Kite, Takeda, Acerta Pharma, GSK, Bayer, Janssen, Karyopharma, Pfizer, ADCT Therapeutics, BioINvent	A,G,H,O	Speaker
Efeyan	Alejo	Spanish National Cancer Research Center, CNIO	No Relationships		Speaker
Elenitoba-Johnson	Kojo	University of Pennsylvania School of Medicine	No Relationships		Program Committee, Speaker
Flowers	Christopher	The University of Texas MD Anderson Cancer Center	AbbVie, Bayer, Beigene, Celgene, Genentech/Roche, Gilead, OptumRx, Karyopharm, Pharmacyclics, Janssen, Spectrum, Acerta, Millennium/Takeda, TG Therapeutics	O	Speaker
Fontan	Lorena	Weill Cornell Medical College	No Relationships		Speaker
Gewurz	Ben	Brigham and Women's Hospital	No Relationships		Speaker
Giulino-Roth	Lisa	Weill Cornell Medical College	No Relationships		Speaker




AACR Virtual Meeting

Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

August 17-19, 2020

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	Company	Relationships	Type	Role
Goodnow	Christopher	Garvan Institute of Medical Research	No Relationships		Speaker
Green	Michael	The University of Texas MD Anderson Cancer Center	Verastem Oncology, KDAc Therapeutics	A,S,O	Program Committee, Speaker
Greenberger	Lee	The Leukemia & Lymphoma Society	X4 Pharma, BMS, CPRIT, Pfizer	A,C,S	Program Committee
Gutierrez	Meghan	Lymphoma Research Foundation	No Relationships		Program Committee
Heslop	Helen	Baylor College of Medicine	Allovir, Marker Therapeutics, Tessa Therapeutics, Cell Medica, Gilead, Novartis, PACT Pharma, Kiadis	A,G,S	Program Committee, Speaker
Horwitz	Steven	Memorial Sloan Kettering Cancer Center	ADC Therapeutics, Aileron, Astex Pharmaceuticals, Beigene, Celgene Corporation, Curio, Daiichi- Sankyo Co., Forty Seven Inc., GSK, Kyowa Hakko Kirin Co., Merck & Co. Inc., Miragen, Myeloid Therapeutics, Portola Pharmaceuticals Inc., Seattle Genetics Inc., Takeda/ Millennium, Trillium, Verastem,	A,C,G	Speaker
Hunter	Zachary	Dana-Farber Cancer Institute	Janssen, Pharmacyclics	A,H	Speaker
Inghirami	Giorgio	Weill Cornell Medicine	No Relationships		Speaker
Intlekofer	Andrew	Memorial Sloan Kettering Cancer Center	No Relationships		Speaker
Ji	Hanlee	Stanford University	No Relationships		Speaker
Johnson	Peter	University of Southampton	Takeda, Bristol-Myers Squibb, Novartis, Celgene, Kite Pharma, Genmab, Incyte, Morphosys, Kymera, Janssen, Oncimmune, Epizyme, Inivata, Roche, BC Platforms	A,G,H	Program Committee, Speaker
Johnstone	Ricky	Peter MacCallum Cancer Centre	Roche, MecRx, BMS, AZ	C,G,H,S	Program Committee
Kataoka	Keisuke	National Cancer Center, Japan	Asahi Genomics, Otsuka Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical	G,S	Speaker




AACR Virtual Meeting

Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

August 17-19, 2020

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	Company	Relationships	Type	Role
Keegan	Theresa	University of California Davis	No Relationships		Speaker
Kelly	Kara	Roswell Park Comprehensive Cancer Center	Merck, BMS	O	Program Committee, Speaker
Kipps	Thomas	University of California San Diego Moores Cancer Center	Oncternal Therapeutics, Pharmacyclics/AbbVie, BCRF, LLS, SCOR	A,G,S	Program Committee
Kurtz	David	Stanford University	Roche	C	Speaker
Lenz	Georg	University of Münster	Roche, Gilead, Janssen, Bayer, Celgene, Novartis, AZ, Takeda, BMS, NanoString, AbbVie	A,H	Program Committee, Speaker
Leonard	John	Weill Cornell Medical College	Sutro, Miltenyi, AstraZeneca, Epizyme, Roche/Genentech, BMS/Celgene, Regeneron, ADC Therapeutics, MEI Pharma, Bayer, Gilead/Kite, Karyopharm	C	Program Committee
Louissaint	Abner	Massachusetts General Hospital	No Relationships		Speaker
Mamonkin	Max	Baylor College of Medicine	No Relationships		Speaker
Melnick	Ari	Weill Cornell Medical College	Constellation Pharmaceuticals, Epizyme Inc., Janssen Biotech, Sanofi US Services, KDAC Therapeutics.	C,G,S	Program Committee, Speaker
Morin	Ryan	Simon Fraser University	Celgene	C	Speaker
Nadel	Bertrand	Centre d'Immunologie de Marseille-Luminy	Celgene/BMS, Gilead	G,H	Program Committee, Speaker
Neelapu	Sattva	The University of Texas MD Anderson Cancer Center	Kite/Gilead, Merck, BMS/Celgene, Novartis, Cellectis, Poseida, Allogene, Legend Biotech, Unum Therapeutics, Precision Biosciences	A,C,G	Speaker
Nolan	Garry	Stanford Hospital	Akoya Biosciences, Ionpath	A,S	Speaker
Nowakowski	Grzegorz	Mayo Clinic College of Medicine	Nanostrings, Celgene/BMS, Roche/Genentech	A,G	Speaker
Ogawa	Seishi	Kyoto University Graduate School of Medicine	No Relationships		Program Committee




AACR Virtual Meeting

Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

August 17-19, 2020

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	Company	Relationships	Type	Role
Okosun	Jessica	Queen Mary, Univ. of London	No Relationships		Speaker
Palomero	Teresa	Columbia University	Kura Oncology	G	Program Committee, Speaker
Pasqualucci	Laura	NY Presbyterian Hospital Herbert Irving Comprehensive Cancer Center	No Relationships		Speaker
Rossi	Davide	Institute of Oncology Research	AbbVie, AstraZeneca, Verastem, Janssen	G,H	Speaker
Roulland	Sandrine	Centre d'Immunologie de Marseille-Luminy	Celgene	G	Speaker
Salles	Gilles	Lyon-Sud Charles Mérieux Medical School	No Relationships		Program Committee
Savage	Kerry	BC Cancer	BMS, Merck, Seattle Genetics, AstraZeneca, Gilead, Abbvie, Servier, Beigene	C,H,O	Program Committee
Scott	David	BC Cancer	Celgene, Janssen, Abbvie, Roche/Genentech, NanoString	A,C,G	Speaker
Seymour	John	Peter MacCallum Cancer Centre	AbbVie, Acerta, BMS, Gilead, Janssen, Mei Pharma, Roche, Celgene	A,C,G,H,SB	Program Committee, Speaker
Shipp	Margaret	Dana-Farber Cancer Institute	BMS, Merck, Bayer, Ono Pharmaceutical, Celgene	G,H	Program Committee
Singh	Ankur	Georgia Institute of Technology	No Relationships		Speaker
Smith	Sonali	University of Chicago Medical Center	Genentech, TG Therapeutics, Celgene	C	Program Committee, Speaker
Staudt	Louis	National Cancer Institute	No Relationships		Program Committee, Speaker
Steidl	Christian	BC Cancer	Seattle Genetics; Curis Inc.; Roche, AbbVie; Juno Therapeutics; Bayer; Bristol-Myers Squibb; Trillium Therapeutics Inc.	C,G	Program Committee, Speaker
Tam	Constantine	St. Vincent's Hospital Sydney	Janssen, AbbVie, Beigene	G,H	Speaker
Tarte	Karin	Université de Rennes	No Relationships		Speaker



AACR Virtual Meeting

Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

August 17-19, 2020

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	Company	Relationships	Type	Role
Victora	Gabriel	The Rockefeller University	No Relationships		Speaker
Weinstock	David	Dana-Farber Cancer Institute	Travera, Mundipharma EDO, Bantam, Ajax, Myeloid Therapeutics, Novartis, Genentech/Roche, Dragonfly, Prescient, Ossium, AZ, Aileron, AbbVie, Daiichi Sankyo, Verastem, Surface Oncology	A,C,G,S,O	Program Committee, Speaker
Weng	Andrew	BC Cancer	Celgene	C	Speaker
Younes	Anas	AstraZeneca	AstraZeneca, Janssen, Curis, Merck, BMS, Syndax, Roche, AbbVie, Epizyme, Takeda, Biopath, Xynomics, Celgene, HCM	E,C,G,H	Program Committee
Zhao	Weili	Shanghai Rui Jin Hospital	No Relationships		Program Committee